CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Completed

Conditions: Myelodysplastic Syndromes
Beta-thalassemia

First Posted Date: 2021-07-22

Last Posted Date: 2024-07-12

Lead Sponsor: Celgene

Target Recruit Count: 187

Registration Number: NCT04973280

Locations: 🇮🇹
Local Institutions, Rome, Italy

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-99677
Other: Placebo

First Posted Date: 2021-07-12

Last Posted Date: 2022-11-04

Lead Sponsor: Celgene

Target Recruit Count: 25

Registration Number: NCT04958291

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
🇺🇸
Local Institution - 001, Long Beach, California, United States

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Phase 1

Active, not recruiting

Conditions: Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions: Drug: CC-91633

First Posted Date: 2021-07-07

Last Posted Date: 2025-05-11

Lead Sponsor: Celgene

Target Recruit Count: 180

Registration Number: NCT04951778

Locations: 🇪🇸
Local Institution - 301, Barcelona, Spain
🇺🇸
Local Institution - 107, Boston, Massachusetts, United States
🇺🇸
Local Institution - 101, Boston, Massachusetts, United States

and more 6 locations

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Phase 2

Terminated

Conditions: Spondylitis, Ankylosing

Interventions: Drug: CC-99677
Other: Placebo

First Posted Date: 2021-07-01

Last Posted Date: 2024-05-01

Lead Sponsor: Celgene

Target Recruit Count: 167

Registration Number: NCT04947579

Locations: 🇵🇱
Local Institution - 311, Bialystok, Poland
🇵🇱
Local Institution - 301, Elblag, Poland
🇵🇱
Local Institution - 310, Nowa Sol, Poland

and more 60 locations

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Iberdomide

First Posted Date: 2021-06-22

Last Posted Date: 2023-02-15

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT04933747

Locations: 🇺🇸
Local Institution - 002, Knoxville, Tennessee, United States
🇺🇸
Local Institution - 003, San Antonio, Texas, United States
🇺🇸
Local Institution - 001, Orlando, Florida, United States

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: CC-486
Drug: Venetoclax

First Posted Date: 2021-05-14

Last Posted Date: 2024-02-12

Lead Sponsor: Celgene

Target Recruit Count: 6

Registration Number: NCT04887857

Locations: 🇺🇸
Local Institution - 105, Boston, Massachusetts, United States
🇺🇸
Local Institution - 102, Cleveland, Ohio, United States
🇦🇺
Local Institution - 201, Melbourne, Australia

and more 7 locations

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma, B-Cell

Interventions: Drug: CC-220
Drug: Rituximab
Drug: Cyclophosphamide
Drug: CC-99282
Drug: Doxorubicin
Drug: Vincristine
Drug: Polatuzumab vedotin
Drug: Prednisone

First Posted Date: 2021-05-12

Last Posted Date: 2025-03-24

Lead Sponsor: Celgene

Target Recruit Count: 174

Registration Number: NCT04884035

Locations: 🇬🇷
Local Institution - 703, Patras, Greece
🇨🇳
Taichung Veterans General Hospital, Taichung City, Taiwan
🇺🇸
Mayo Clinic - Arizona, Scottsdale, Arizona, United States

and more 31 locations

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma, B-Cell

Interventions: Drug: CC-220
Drug: Rituximab
Drug: Tafasitamab
Drug: Polatuzumab vedotin
Drug: Gemcitabine
Drug: Lenalidomide
Drug: Cisplatin
Drug: Bendamustine
Drug: Dexamethasone

First Posted Date: 2021-05-11

Last Posted Date: 2021-10-05

Lead Sponsor: Celgene

Registration Number: NCT04882163

Locations: 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

and more 24 locations

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: CC-96673

First Posted Date: 2021-04-27

Last Posted Date: 2024-10-16

Lead Sponsor: Celgene

Target Recruit Count: 100

Registration Number: NCT04860466

Locations: 🇫🇷
Local Institution - UNK-5, Angers, France
🇫🇷
Local Institution - 303, Lille, France
🇫🇷
Local Institution - 302, Montpellier CEDEX 5, France

and more 10 locations

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: BB2121
Drug: CC-220
Drug: BMS-986405

First Posted Date: 2021-04-22

Last Posted Date: 2025-05-15

Lead Sponsor: Celgene

Target Recruit Count: 21

Registration Number: NCT04855136

Locations: 🇺🇸
Local Institution - 109, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 114, Chicago, Illinois, United States
🇺🇸
Local Institution - 108, Boston, Massachusetts, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy